Autres langues Takeda Pharmaceutical Company Limited NYSE

Actions

TAK

US8740602052

Produits pharmaceutiques

Marché Fermé - NYSE 22:00:02 28/08/2026			Varia. 5j.	Varia. 1 janv.
18,03 ^USD	0,00%		-0,83%	+15,65%

15:23	Takeda Pharmaceutical Company Limited reçoit l'approbation de la FDA américaine pour le MIMRYLO dans le traitement de l'érythrocytose chez les adultes atteints de polyglobulie essentielle	CI
28/08	La FDA américaine approuve le médicament de Takeda et Protagonist contre un cancer du sang rare	RE

Autres langues

15:23	Takeda Pharmaceutical Company Limited Receives U.S. FDA Approval Of MIMRYLO For Treatment Of Erythrocytosis In Adults With Polycythemia Vera
00:41	Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera
28/08	US FDA approves Takeda, Protagonist's drug for rare blood cancer
28/08	Takeda's Mimrylo Gets FDA Approval to Treat Blood Cancer Condition
28/08	Novavax, Inc., Sanofi S.A., And Takeda Pharmaceutical Company Limited Receive Approvals For XFG-Adapted Nuvaxovid Formulation In The U.S., European Union And Japan For 2026-2027 Vaccination Season
28/08	Novavax's Nuvaxovid Approved in US, EU, Japan for 2026-2027 Season
24/08	Takeda Pharmaceutical : Provides Update on ADZYNMA (ADAMTS13, recombinant-krhn)
24/08	FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndrome
24/08	Takeda's Orzeryful Approved in Japan as First Treatment Targeting Narcolepsy Type 1
24/08	Takeda Pharmaceutical Company Limited Receives Approval For Orzeyful (Oveporexton) To Treat Narcolepsy Type 1 In Japan
24/08	Takeda Secures Japan Approval for Orzeyful to Treat Narcolepsy Type 1
24/08	ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
20/08	Pharma sector doubles down on AI amid hopes of slashing costs, timelines
18/08	Asian Equities Traded in the US as American Depositary Receipts Track Lower in Tuesday Trading
13/08	Takeda Pharmaceutical Insider Sold Shares Worth $1,523,439, According to a Recent SEC Filing
13/08	Takeda Pharmaceutical Insider Sold Shares Worth $2,828,220, According to a Recent SEC Filing
06/08	Takeda Wins FDA Approval for First-in-Class Narcolepsy Treatment ORZEYFUL
06/08	Takeda Receives U.S. Fda Approval for Orzeyful (Oveporexton) to Treat Narcolepsy Type 1
06/08	U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
05/08	US FDA approves Takeda's sleep disorder pill
05/08	Takeda Pharmaceutical Seeks India's Backing for Landmark Dengue Shot
30/07	Keros Therapeutics to Receive $20 Million Development Milestone Payment From Takeda
30/07	Takeda Pharmaceutical Company Limited Provides Impairment of Intangible Assets Guidance for the Fiscal Year ending March 31, 2027
30/07	Takeda Pharmaceutical Profit Drops 9% in Fiscal Q1
30/07	Takeda Pharmaceutical Fiscal Q1 Core Earnings, Revenue Rise